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558a Tuesday, February 28, 2012cMyBP-C is altered during heart failure (HF). There are several identified phos-
phorylated residues, including the regulatory phosphorylation sites Ser275,
Ser284 and Ser304. Methods: Comparison of the extent of MyBP-C phosphor-
ylation status in failing (N=10) and non-failing (N=10) human left ventricle
(LV) tissue. The myofilament subproteome was extracted using the ‘IN Se-
quence’ method prior to analysis with some samples dephosphorylated using
alkaline phosphatase as control. Sample analysis was carried out using gel-
(e.g. phos-tag) and mass spectrometry (MS)-based methods. Results: Using
an MS-based phospho-peptide (Ti02 chromatography) enrichment strategy
we identified novel phosphorylation sites at residues Ser286 and Thr290, lo-
cated in the M-motif. These sites were as well observed in MyBP-C from
LV canine hearts. A novel site at residue Thr1109, the titin binding domain
C9, was only observed in the samples without phospho-enrichment. Our results
indicate a marked reduction in cMyBP-C phosphorylation at residues Ser284,
Ser286, Thr290 and Thr1109 in end-stage HF compared to the non-failing
group. Conclusion: This study provides evidence for novel phosphorylation
sites on cMyBP-C both in human and canine hearts and reduced phosphoryla-
tion levels in the end-stage failing heart.
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Recombinant N-terminal domains of cardiac myosin binding protein C
(cMyBP-C) increase calcium-sensitivity of force and the rate of tension rede-
velopement (ktr) when added to permeabilized rat trabeculae. We previously
demonstrated that the regulatory domain of cMyBP-C, referred to as the
MyBP-C motif (or ‘‘M domain’’), is required for these effects. Here we inves-
tigated the effects of single amino acid missense substitutions within the M-do-
main that are associated with human hypertrophic cardiomyopathy (HCM) on
force development and ktr in permeabilized trabeculae from rat right ventricles.
Individual substitutions (R322Q, E330K, V338D, and L348P) were introduced
into a recombinant mouse C1C2 protein (encompassing domains C1-M-C2 of
murine cMyBP-C) by site directed mutagenesis and effects were compared to
wild-type C1C2. All four of the mutations affected the ability of C1C2 to aug-
ment force. Whereas 5 mM wild-type C1C2 induced a pronounced leftward
shift in Ca2þ sensitivity of tension (~0.5 pCa units) and increased ktr at all sub-
maximal Ca2þ concentrations, 3 of the mutations reduced the effects of C1C2.
Another variant increased the efficacy of C1C2 and increased passive force in-
dependent of Ca2þ, but reduced maximal Ca2þ activated force. Together
these results indicate that cMyBP-C variants associated with HCM could di-
rectly disrupt sarcomere contractile properties through gain or loss of func-
tional effects and that at least some cMyBP-C missense mutations may cause
disease through a poison polypeptide mechanism. This work is supported by
NIH HL080367 to SPH and a DOD NDSEG graduate fellowship to KLB.
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Cardiac myosin binding protein-C (cMyBP-C) is a member of the immuno-
globulin (Ig) superfamily of proteins and consists of 8 Ig- and 3 fibronectin
(Fn)-like domains along with a unique regulatory sequence referred to as the
MyBP-C ‘‘motif’’ or M-domain. Previously we used atomic force microscopy
(AFM) to investigate the mechanical properties of the different domains of mu-
rine cMyBP-C expressed using a baculovirus/insect cell expression system. To
investigate whether the mechanical properties of cMyBP-C are conserved
across species, here we used AFM to investigate the mechanical properties
of human recombinant cMyBP-C expressed using a baculovirus/insect cell
expression system and native cMyBP-C purified from bovine heart. AFM
force-extension spectra were obtained from cMyBP-C molecules by randomly
adhering individual molecules to the tip of an AFM cantilever and moving the
cantilever to impose a load that stretched the molecules. Results show that the
spectra for the human recombinant and bovine native proteins are remarkably
similar with the first Ig/Fn-like domain unfolding events occurring at low
(~50 pN) forces and the highest stability domains unfolding at ~190 pN. Exper-
iments also revealed frequent unfolding events that appeared coupled such that
lower stability domains would often unfold after higher stability domains.
These unexpected force ‘‘drops’’ were highly reproducible and occurred in
spectra from both human cMyBP-C and bovine cMyBP-C. In addition, both re-
combinant and native cMyBP-C exhibited an ~100 nm long extensible regionthat could be stretched with less than 50 pN force prior to the unfolding of Ig
and Fn-like domains. Combined with our previous results from mouse cMyBP-
C, these results establish common mechanical features of cMyBP-C across spe-
cies. Supported by NIH HL080367.
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Cardiac myosin binding protein-C (cMyBP-C) is a modular protein involved in
stabilizing interactions with the thick filament of the sarcomere. The N-termi-
nus of cMyBP-C associates with actin and myosin S2 and the C-terminus inter-
acts with titin and myosin rods. While no high-resolution structure of C-
terminal cMyBP-C exists, disruption of this region is proposed to destabilize
cMyBP-C and adversely affect cardiac structure and function. In particular, de-
letion of 25 base pairs (D25) in the gene encoding for cMyBP-C results in
amino acid substitutions in the C10 domain of cMyBP-C (C10 D25) which
may be associated with the development of hypertrophic and dilated cardiomy-
opathies by unknown molecular mechanisms. The prevalence of this mutation
is approximately 1% of the world population, underscoring the necessity of de-
termining its role(s) in the pathogenesis of cardiomyopathies. In this study, cir-
cular dichroism (CD) and nuclear magnetic resonance (NMR) spectroscopies
have been used to examine the conformation of wild-type (Wt) and mutant
C-terminal domains of cMyBP-C. Comparison of near UV CD spectra revealed
alterations in the packing of aromatic residues in C10 D25 suggesting it is less
stably folded as compared to C10 Wt. C10 D25 exhibited less beta-sheet con-
tent than C10 Wt as evidenced by the estimation of secondary structure from
CD data. NMR analyses of amide proton/nitrogen chemical shifts and line-
widths were used to probe the conformation of C10 domains and to map resi-
dues of importance in protein-protein association onto cMyBP-C models.
Taken together, these data suggest that theD25 mutation structurally modulates
cMyBP-C sites involved in binding titin and myosin.
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Phosphodiesterase (PDE4DE): Implications for a Possible Role in Heart
Failure
Abeer Rababa’h, John Craft, Cori Wijaya, Bradley K. McConnell.
University of Houston, Houston, TX, USA.
Heart failure is a leading cause of morbidity and mortality in the USA. There
are several therapeutic agents available for heart failure management. In partic-
ular, agents that block beta-adrenergic receptor improve mortality rate among
heart failure patients by enhancing cardiac function. Beta-adrenergic receptor
stimulation signals through protein kinase A (PKA) dependent phosphoryla-
tion, partly by binding to A-kinase anchoring proteins, influencing calcium ho-
meostasis. In particular, mAKAP (muscle-selective A-kinase anchoring
protein) is targeted to specific intracellular compartments resulting in localiza-
tion of PKA with its substrates as well as to bind with ryanodine receptors and
phosphodiesterase-4D3 (PDE4DE). The signal transduction complex formed
by the scaffold protein mAKAP at the perinuclear envelop of striated myocytes
contains cAMP specific binding protein PDE4D3 which is responsible for
cAMP signaling termination. Agents that modify PKA signaling would be ex-
pected to mediate an altered inotropic response. From different genomic data-
bases, we have recently identified fifteen human mAKAP coding non-
synonymous polymorphisms located within or near key protein binding sites
critical to beta-adrenergic receptors signaling. Seven of these mutants were
cloned for the purpose of comparing whether those substitution disrupt mA-
KAP binding to either the PKA binding domain R2alpha or the phosphodiester-
ase PDE4DE. Using surface plasmon resonance (Biacore 2000) we
demonstrate specific binding of wild type mAKAP to PDE4DE. Experiments
were run in triplicate and as twofold serial dilutions to explore the kinetics
of the interaction and analyzed using Scrubber2 with a 1:1 Langmuir model.
Comparative analysis of the binding responses of mutations to mAKAP could
provide important information about how these mutations modulate signaling.
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Recently, a mutation in the 10th immunoglobulin(Ig)-like domain in
titin’s elastic I-band was found in a family affected with arrhythmogenic
